Stockscreener 앱 받기
3.10
54.23%
1.09
시간 외 거래:
3.11
0.010
+0.32%
전일 마감가:
$2.01
열려 있는:
$2.13
하루 거래량:
70.39M
Relative Volume:
57.84
시가총액:
$29.08M
수익:
$2.14M
순이익/손실:
$-15.44M
주가수익비율:
-1.0017
EPS:
-3.0946
순현금흐름:
$-24.67M
1주 성능:
+63.16%
1개월 성능:
+7.27%
6개월 성능:
-20.31%
1년 성능:
-85.59%
1일 변동 폭
$2.06
$3.8599
1주일 범위
$1.8043
$3.8599
52주 변동 폭
$1.50
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
명칭
Tvardi Therapeutics Inc
전화
(713) 489-8654
주소
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
3.10 | 18.86M | 2.14M | -15.44M | -24.67M | -3.0946 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-20 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-10-14 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-10-14 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-10-13 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-14 | 개시 | Raymond James | Outperform |
| 2025-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-12 | 개시 | Piper Sandler | Overweight |
| 2025-05-21 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 개시 | BTIG Research | Buy |
| 2024-06-13 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | 다운그레이드 | Needham | Buy → Hold |
| 2024-06-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-03-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-11-01 | 재개 | Canaccord Genuity | Buy |
| 2021-08-03 | 개시 | JP Morgan | Neutral |
| 2020-04-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-29 | 재확인 | Laidlaw | Buy |
| 2019-02-06 | 재개 | Jefferies | Buy |
| 2019-01-15 | 개시 | BofA/Merrill | Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Jefferies | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-12 | 재개 | H.C. Wainwright | Buy |
| 2018-02-12 | 업그레이드 | Janney | Neutral → Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
모두보기
Tvardi Therapeutics Inc 주식(TVRD)의 최신 뉴스
Tvardi Therapeutics (TVRD) Study result Summary - Quartr
Why Tvardi Therapeutics (TVRD) Stock Is Up Today - Quiver Quantitative
TVRD Reiterated by BTIG -- Price Target Maintained at $15.00 - GuruFocus
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) stock jumps as Phase 1 data puts cash-value biotech under heavy churn - TechStock²
Why Is Tvardi Therapeutics Stock Gaining Tuesday? - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109 - Investorideas.com
With tardy Tvardi phase I win, skin in STAT3 game plus GI - BioWorld News
Tvardi reports 60% immune cell reductions - grafa.com
Tvardi Therapeutics Announces Phase 1 Results For TTI-109 And Plans Advancement Into Dermatologic And Gastrointestinal Diseases - marketscreener.com
Tvardi reports phase 1 results for STAT3 inhibitor TTI-109 - Investing.com
Tvardi Therapeutics Reports Phase 1 Data for TTI-109 - TipRanks
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement - The Manila Times
Tvardi Therapeutics reports Phase 1 TTI-109 data showing bioequivalence to TTI-101, improved tolerability - TradingView
Tvardi Therapeutics (NASDAQ: TVRD) unveils Phase 1 TTI-109 data and plans Phase 2 trials - Stock Titan
Tvardi says TTI-109 matched exposure, cut diarrhea in phase 1 - Stock Titan
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Tvardi Therapeutics Inc. Actuals & Estimates (NASDAQ:TVRD) - TradingView
Price to book forward of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView
Enterprise value to EBIT forward of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView
Enterprise value to revenue forward of Tvardi Therapeutics Inc. – MUN:69C - TradingView
Price to earnings forward of Tvardi Therapeutics Inc. – MUN:69C - TradingView
Tvardi Therapeutics Inc. Actuals & Estimates (LSE:0HTC) - TradingView
Price to earnings forward of Tvardi Therapeutics Inc. – LSE:0HTC - TradingView
TVRD Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView
H.C. Wainwright Maintains Tvardi Therapeutics(TVRD.US) With Buy Rating, Maintains Target Price $9 - Moomoo
SGMOQ Stock Price and Chart — OTC:SGMOQ - TradingView
Price to sales forward of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView
Price to sales forward of Tvardi Therapeutics Inc. – LSE:0HTC - TradingView
TVRD PE Ratio & Valuation, Is TVRD Overvalued - Intellectia AI
Tvardi Therapeutics Ord Shs (TVRD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tvardi Therapeutics Ord Shs (TVRD) Institutional Confidence - TradingKey
Tvardi Therapeutics Ord Shs (TVRD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tvardi Therapeutics (TVRD) Slides as Stock Approaches Key Support Near $2.51Growth ETF - newsline.com
TVRD Q1 2026 Earnings: Narrowed Loss Per Share Beats Expectations Amid Pipeline ProgressEstimate Dispersion - newsline.com
Tvardi Therapeutics Shareholders Approve Directors and Governance Measures - The Globe and Mail
Tvardi Therapeutics Inc. (TVRD) Q1 2026 Earnings: Beats EPS Estimates Amid Continued R&D Progress - newsline.com
Tvardi Therapeutics (TVRD) grants 6,000 stock options to director - Stock Titan
Tvardi Therapeutics (TVRD) director granted 6,000 options at $2.78 exercise price - Stock Titan
Tvardi Therapeutics (TVRD) director Sujal Shah awarded 6,000 stock options at $2.78 - Stock Titan
Tvardi Therapeutics (TVRD) director receives grant of 6,000 stock options at $2.78 - Stock Titan
Tvardi Therapeutics (TVRD) director awarded 6,000 stock options at $2.78 - Stock Titan
Tvardi Therapeutics (TVRD) investors approve directors, say-on-pay and Deloitte as 2026 auditor - Stock Titan
Tvardi Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Shiff Susan Ph.D. - Moomoo
Tvardi Therapeutics (TVRD) Declines 2.88% as Stock Tests Key Support; Near-Term Outlook Hinges on $2.56 FloorFactor Momentum - newsline.com
Tvardi Therapeutics (TVRD) Dips 2.88% as Shares Test Near-Term SupportLeading Diagonal - dars.gov.et
This Cerebras Systems analyst begins coverage on a bullish note; here are top 3 initiations for Monday - MSN
Tvardi Therapeutics Inc (TVRD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.17%
2.48%
자본화:
|
볼륨(24시간):